Legal & General Group Plc Buys New Position in Certara, Inc. $CERT

Legal & General Group Plc purchased a new position in shares of Certara, Inc. (NASDAQ:CERT) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 265,727 shares of the company’s stock, valued at approximately $1,741,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares in the last quarter. State of Wyoming bought a new position in shares of Certara during the second quarter valued at about $72,000. Finally, Pacer Advisors Inc. boosted its holdings in Certara by 28.1% during the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CERT shares. BMO Capital Markets decreased their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird cut their target price on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. Stephens reduced their target price on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Finally, Barclays lifted their price target on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Certara has a consensus rating of “Hold” and an average target price of $8.28.

Certara Stock Performance

NASDAQ:CERT opened at $7.94 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55. The business has a fifty day simple moving average of $7.63 and a two-hundred day simple moving average of $6.52. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a market capitalization of $1.21 billion, a P/E ratio of -17.64 and a beta of 1.40.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $93.27 million during the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The company’s revenue was down 10.8% compared to the same quarter last year. During the same period last year, the business posted $0.07 EPS. On average, analysts expect that Certara, Inc. will post 0.22 earnings per share for the current year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.